NicVax: Phase II data

In a double-blind, placebo-controlled, U.S. Phase II trial in 68 smokers, 200 µg NicVAX gave a 33% quit rate vs. 9% for placebo. Patients were given 1 of 3 doses of NicVax (50, 100 or 200 µg) or place...